Literature DB >> 28699092

Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer.

Nobuaki Hoshino1, Kenji Kawada2, Koya Hida2, Saori Goto2, Ryuji Uozumi3, Suguru Hasegawa4, Kenichi Sugihara5, Yoshiharu Sakai2.   

Abstract

One of the reasons for the underuse of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is a small survival benefit. This retrospective study sought to identify the predictive factors for elderly patients who could obtain a sufficient survival benefit. We reviewed the data of 1354 elderly patients (aged ≥70 years) with stage III colorectal cancer who underwent complete resection between January 1997 and December 2006. The efficacy of adjuvant chemotherapy was assessed, and the risk factors for recurrence were determined. The efficacy of adjuvant chemotherapy was also assessed after stratification for the above-mentioned risk factors for recurrence. There was a tendency for adjuvant chemotherapy to be effective in elderly patients (hazard ratio 0.84; 95% CI 0.70-1.01). Age, tumor location, pathology findings, tumor depth, venous invasion and lymph node metastasis were identified to be independent risk factors for recurrence by univariate and multivariate analyses. Among these factors, adjuvant chemotherapy was much effective in the elderly patients with high venous invasion (v2-3) (hazard ratio 0.69; 95% CI 0.52-0.91). High venous invasion (v2-3) was identified to be a predictive factor for elderly patients with stage III colorectal cancer who gained a sufficient survival benefit.

Entities:  

Keywords:  Adjuvant chemotherapy; Colorectal neoplasms; Elderly; Stage III

Mesh:

Year:  2017        PMID: 28699092     DOI: 10.1007/s12032-017-0996-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  24 in total

1.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

2.  Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Authors:  Julien Taieb; Josep Tabernero; Enrico Mini; Fabien Subtil; Gunnar Folprecht; Jean-Luc Van Laethem; Josef Thaler; John Bridgewater; Lone Nørgård Petersen; Hélène Blons; Laurence Collette; Eric Van Cutsem; Philippe Rougier; Ramon Salazar; Laurent Bedenne; Jean-François Emile; Pierre Laurent-Puig; Come Lepage
Journal:  Lancet Oncol       Date:  2014-06-11       Impact factor: 41.316

3.  Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer.

Authors:  H J Chang; K-W Lee; J H Kim; S M Bang; Y J Kim; D W Kim; S B Kang; J S Lee
Journal:  Ann Oncol       Date:  2011-08-04       Impact factor: 32.976

4.  Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.

Authors:  C Twelves; W Scheithauer; J McKendrick; J-F Seitz; G Van Hazel; A Wong; E Díaz-Rubio; F Gilberg; J Cassidy
Journal:  Ann Oncol       Date:  2011-09-06       Impact factor: 32.976

5.  Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.

Authors:  Neal W Wilkinson; Greg Yothers; Samia Lopa; Joseph P Costantino; Nicholas J Petrelli; Norman Wolmark
Journal:  Ann Surg Oncol       Date:  2010-04       Impact factor: 5.344

6.  Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.

Authors:  Hans-Joachim Schmoll; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Silke Hoersch; Karen Rittweger; Daniel G Haller
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

7.  Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study.

Authors:  Ki-Yeol Kim; In-Ho Cha; Joong Bae Ahn; Nam Kyu Kim; Sun Young Rha; Hyun Cheol Chung; Jae Kyung Roh; Sang Joon Shin
Journal:  J Surg Oncol       Date:  2012-11-28       Impact factor: 3.454

8.  The clinical utility of the combination of T stage and venous invasion to predict survival in patients undergoing surgery for colorectal cancer.

Authors:  Campbell S D Roxburgh; Donald C McMillan; Colin H Richards; Manal Atwan; John H Anderson; Tim Harvey; Paul G Horgan; Alan K Foulis
Journal:  Ann Surg       Date:  2014-06       Impact factor: 12.969

9.  Prognostic value of the number and size of venous invasions in pT3 colorectal cancer: a prospective observational study.

Authors:  Eiji Shinto; Hitoshi Tsuda; Hideki Ueno; Hideyuki Shimazaki; Junji Yamamoto; Kazuo Hase
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

10.  Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.

Authors:  Jenny J Ko; Hagen F Kennecke; Howard J Lim; Daniel J Renouf; Sharlene Gill; Ryan Woods; Caroline Speers; Winson Y Cheung
Journal:  Clin Colorectal Cancer       Date:  2015-09-30       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.